deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03430895

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Metastatic, Non-transitional Cell Carcinoma of the Urothelial Tract

Sponsor: AstraZeneca

Conditions Adenocarcinoma of the Bladder Metastatic Bladder Cancer Non-Transitional Cell Carcinoma of the Urothelial Tract Small Cell of the Bladder Squamous Cell Carcinoma of the Bladder
Interventions durvalumab and tremelimumab
Updated 10 times since 2018 Last updated: Nov 3, 2021 Started: Jan 31, 2018 Primary completion: Feb 10, 2021 Completion: Feb 10, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03430895, this PHASE2 trial focuses on Adenocarcinoma of the Bladder and Metastatic Bladder Cancer and remains completed. Sponsored by AstraZeneca, it has been updated 10 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotRecruiting~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshotRecruiting~Jan 2019 – ~Nov 2019 · 10 months · monthly snapshotRecruiting~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshotActive Not Recruiting~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotActive Not Recruiting~Mar 2021 – ~Jan 2022 · 10 months · monthly snapshotCompleted~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Mar 2021 — Jan 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

▶ Show 5 earlier versions

  1. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jan 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  4. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  5. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations